The US FDA has approved Bexlutry (lutetium Lu 177 dotatate), a radioligand therapy from Boston-based Curium, for the ...

QurCan Therapeutics and Lilly will develop nucleic acid therapies for CNS and PNS diseases. See what the partnership means ...

FDA launches its Expedited IND Pilot and invites applications by Oct. 30, 2026. See how early-phase trial partners can apply ...

MaaT013 faces a second negative CHMP trend vote in Europe, clouding its path to approval. Read the latest update on MaaT ...

GSK will acquire Chimagen’s preclinical trispecific T-cell engager for up to $750 million. See what the deal means for ...

Cellectis is ending CAR-T development to focus on in vivo gene editing for metabolic diseases. Read about the strategy shift ...

Novo Nordisk is becoming Novo with a new culture framework and identity. See how the rebrand aims to strengthen its competitive edge.

Definium's DT120 earns a second positive Phase III GAD result, supporting a planned 2027 NDA filing. Read the latest trial ...

One04 Therapeutics launches with CPV-104 Phase 1 data, D11Z.Ventures backing and plans for kidney disease and dry AMD trials. Read more.

Tyra Biosciences priced a $400M offering to fund dabogratinib trials in bladder cancer and achondroplasia. See the deal and ...

Cardiff Oncology and Nerviano settle the onvansertib license dispute ahead of a planned Phase III trial. Read the latest deal ...

Santa Ana Bio begins first-in-human testing of SAB01, a bispecific antibody targeting mast cells for autoimmune and ...